Q4 2024 Tandem Diabetes Care Inc Earnings Call Transcript
Key Points
- Tandem Diabetes Care Inc (TNDM) achieved an 18% increase in worldwide sales in 2024, setting new sales records both in the US and internationally.
- The introduction of the Tandem Mobi pump platform was a highlight, experiencing continued growth and expanding the company's product portfolio.
- The company implemented operational efficiencies that set the stage for sustained profitability in 2025 and beyond.
- Tandem's Control-IQ Plus algorithm, now FDA cleared for people with type 2 diabetes, more than doubles the addressable market in the United States.
- The company has made significant progress in expanding its pharmacy channel, with approximately 20% of US lives covered under pharmacy agreements, improving access and affordability for patients.
- The fourth quarter in the US did not meet expectations due to muted seasonality and shipping delays, impacting revenue reporting.
- The transition to direct sales in select European countries may cause some disruption, potentially affecting sales in 2025.
- The sales force expansion and realignment in the US could create short-term disruption, impacting sales performance.
- Despite the positive outlook, the company faces a highly competitive market with more competitors and larger sales forces.
- The pharmacy channel and type 2 diabetes market initiatives are still in early stages, with only modest contributions expected in 2025.
Good day and welcome to the Tandem Diabetes fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Susan Morrison, executive Vice President and Chief Administrative Officer. Please go ahead.
Hello everyone, and thanks for joining Tandem's fourth quarter and year-end 2024 earnings call. Today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, our product pipeline, development timelines, and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements.
A list of factors that could cause actual results to be materially different from those expressed or implied by any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
